Home » Stocks » OVID

Ovid Therapeutics Inc. (OVID)

Stock Price: $2.47 USD -0.10 (-3.89%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $2.55 +0.08 (3.24%) Jan 15, 7:59 PM
Market Cap 156.68M
Revenue (ttm) 6.91M
Net Income (ttm) -75.98M
Shares Out 59.41M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $2.47
Previous Close $2.57
Change ($) -0.10
Change (%) -3.89%
Day's Open 2.61
Day's Range 2.46 - 2.65
Day's Volume 1,477,735
52-Week Range 2.03 - 8.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...

InvestorPlace - 1 month ago

Ovid Therapeutics (OVID) news for Wednesday concerning results from a recent clinical trial have OVID stock taking a beating. The post Ovid Therapeutics News: Why OVID Stock Is Plunging 55% To...

The Motley Fool - 1 month ago

The company reported disappointing results from a late-stage clinical trial.

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinic...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...

GlobeNewsWire - 3 months ago

NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare n...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

Seeking Alpha - 4 months ago

Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive Data

GlobeNewsWire - 4 months ago

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rar...

GlobeNewsWire - 4 months ago

NEW YORK and OSAKA, Japan, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biop...

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...

Seeking Alpha - 5 months ago

Ovid Therapeutics Is Quickly Approaching A Transformational Valuation Milestone

The Motley Fool - 5 months ago

Here are the best biotech stocks for investors looking for market-beating performance.

Other stocks mentioned: GBT, MESO
GlobeNewsWire - 5 months ago

NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the live...

The Motley Fool - 6 months ago

One analyst thinks the stock still has significant upside. Is that enough to justify its price?

GlobeNewsWire - 6 months ago

NEW YORK and ROME, July 13, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID, hereinafter “Ovid”), a biopharmaceutical company committed to developing medicines that transform t...

GlobeNewsWire - 6 months ago

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...

Zacks Investment Research - 6 months ago

Ovid Therapeutics (OVID) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...

The Motley Fool - 6 months ago

The small-cap biopharma got a nod from an analyst.

InvestorPlace - 7 months ago

When choosing cheap stocks to invest in you don't always have to sacrifice quality. Here are four high-quality companies that are affordable.

Other stocks mentioned: INVE, PLUG, VG
GlobeNewsWire - 7 months ago

NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...

InvestorPlace - 7 months ago

For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.

Other stocks mentioned: BTG, CSTM, DVAX, INVE, LIVX, PLUG, SQNS, VG, XFOR
GlobeNewsWire - 7 months ago

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...

Seeking Alpha - 8 months ago

Ovid Advances Fragile X Syndrome Drug Forward; Multiple Catalysts Still Expected In 2020

GlobeNewsWire - 8 months ago

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare n...

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for April 22nd

Other stocks mentioned: ASC, CRMD, FUV
24/7 Wall Street - 9 months ago

The coronavirus pandemic has cast the spotlight on the world of biotechnology stocks as researchers search for not only a vaccine, but for additional drugs that can help in the treatment of th...

Other stocks mentioned: GILD, ICPT, ITCI, KPTI
GlobeNewsWire - 10 months ago

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

InvestorPlace - 1 year ago

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

Other stocks mentioned: CDTX, CPE, KDMN, NEX, QEP
InvestorPlace - 1 year ago

Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings. The post 5 Strong Buy Stocks Under $5 With Massive Upside Potential appeared ...

Other stocks mentioned: ITI, MTNB, OGI, PLUG
GlobeNewsWire - 1 year ago

Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team

InvestorPlace - 1 year ago

These stocks come from a variety of industries, but all have positive catalysts in their futures. Buy these cheap stocks now while you can.

Other stocks mentioned: AMC, ANGI, GLUU, ITI, MEET, PLUG, TH, VG, WIFI
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Ovid Therapeutics.

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rar...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rar...

GlobeNewsWire - 1 year ago

Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

24/7 Wall Street - 1 year ago

Despite this truncated trading week, Tuesday was a breakout day for a few biotech companies.

Other stocks mentioned: AMRN, OCUL
Seeking Alpha - 1 year ago

Shares have lost roughly 87% since IPO and fallen by more than 80% since my last update article.

Benzinga - 1 year ago

Ovid Therapeutics Inc. shares have been on a steady downtrend since Aug. 6, 2018, when it released topline data from a Phase 2 study dubbed STARS that evaluated its OV101 for treating a geneti...

About OVID

Ovid Therapeutics, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficie... [Read more...]

Industry
Biotechnology
IPO Date
May 5, 2017
CEO
Jeremy Levin
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
OVID
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 142.91% from the latest price.

Price Target
$6.00
(142.91% upside)
Analyst Consensus: Buy